Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1978-8-28
|
| pubmed:abstractText |
1,25 dihydroxycholecalciferol [1,25(OH)2D3] was studied in a double-blind controlled fashion in patients on chronic dialysis. Serum calcium was unchanged in 16 patients on vitamin D3 (D3) (400 to 1200 IU/day). In 15 patients on 1,25(OH)2D3 (0.5 to 1.5 microgram/day), serum calcium increased from 9.05 +/- .15 to 10.25 +/- .20 mg/dl (p less than 0.001), returning to 9.37 +/- .16 mg/dl (p less than 0.001) in the post control period. Patients on D3 showed no reversible decrease in immunoreactive parathyroid hormone levels, but patients on 1,25(OH)2D3 did, from a control of 1077 +/- 258 to 595 +/- 213 microliter equivalents/ml (p less than 0.01), and returned to 1165 +/- 271 microliter equivalents/ml (p less than 0.005). Nine of 12 patients on D3 who underwent serial iliac-crest biopsies showed histologic deterioration, and six of seven who received 1,25(OH)2D3 were improved or unchanged (p less than 0.025). Bone mineral and calcium decreased in patients on D3 (p less than 0.05) but not in those on 1,25(OH)2D3. Hypercalcemia occurred in five of 15 patients. We conclude that 1,25(OH)2D3 has a calcemic effect in chronic dialysis patients, decreases levels of immunoreactive parathyroid hormone, and is associated with histologic improvement in bone disease. Thus, 1,25(OH)2D3 is a valuable adjunct to the management of renal osteodystrophy but requires monitoring of serum calcium to avoid hypercalcemia.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Alkaline Phosphatase,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium,
http://linkedlifedata.com/resource/pubmed/chemical/Cholecalciferol,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydroxycholecalciferols,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxycholecalciferols,
http://linkedlifedata.com/resource/pubmed/chemical/Minerals,
http://linkedlifedata.com/resource/pubmed/chemical/Parathyroid Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphorus
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0003-4819
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
88
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
774-80
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:208439-Adult,
pubmed-meshheading:208439-Alkaline Phosphatase,
pubmed-meshheading:208439-Antigens,
pubmed-meshheading:208439-Bone and Bones,
pubmed-meshheading:208439-Calcium,
pubmed-meshheading:208439-Cholecalciferol,
pubmed-meshheading:208439-Clinical Trials as Topic,
pubmed-meshheading:208439-Dihydroxycholecalciferols,
pubmed-meshheading:208439-Double-Blind Method,
pubmed-meshheading:208439-Female,
pubmed-meshheading:208439-Humans,
pubmed-meshheading:208439-Hydroxycholecalciferols,
pubmed-meshheading:208439-Hypercalcemia,
pubmed-meshheading:208439-Kidney Failure, Chronic,
pubmed-meshheading:208439-Male,
pubmed-meshheading:208439-Middle Aged,
pubmed-meshheading:208439-Minerals,
pubmed-meshheading:208439-Parathyroid Hormone,
pubmed-meshheading:208439-Phosphorus,
pubmed-meshheading:208439-Renal Dialysis,
pubmed-meshheading:208439-Renal Osteodystrophy
|
| pubmed:year |
1978
|
| pubmed:articleTitle |
1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|